Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31051
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoreno-Pérez, Oscar-
dc.contributor.authorAndres, Mariano-
dc.contributor.authorLEON-RAMIREZ, JOSE-MANUEL-
dc.contributor.authorSánchez-Payá, José-
dc.contributor.authorRodríguez, Juan Carlos-
dc.contributor.authorSánchez, Rosario-
dc.contributor.authorGarcía Sevila, Raquel-
dc.contributor.authorBoix, Vicente-
dc.contributor.authorGil, Joan-
dc.contributor.authorMerino, Esperanza-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-05T12:09:09Z-
dc.date.available2024-02-05T12:09:09Z-
dc.date.created2020-
dc.identifier.citationJournal of Autoimmunity . 2020 Nov:114:102523es_ES
dc.identifier.issn1095-9157-
dc.identifier.urihttps://hdl.handle.net/11000/31051-
dc.description.abstractObjectives: To describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia.Patients and methods: Case series of all sequential patients with severe COVID-19 pneumonia treated with TCZ at an Academic Spanish hospital (March 12 - May 2, 2020). Clinical outcomes: death, length of hospital stay. An early clinical response to TCZ (48-72 h after the administration) was assessed by variations in respiratory function markers, Brescia COVID Respiratory Severity Scale (BCRSS), inflammatory parameters, and patients' and physicians' opinion. Associations were tested by multiple logistic regression.Results: From a cohort of 236 patients, 77 patients treated with TCZ were included (median age 62 years (IQR 53.0-72.0), 64.9% were males), 42.9% had Charlson index ≥3; hypertension (41.6%), obesity (34.7%), and diabetes (20.8%). Median follow-up was 83.0 days (78.0-86.5), no patient was readmitted. ICU admission was required for 42 (54.5%), invasive mechanical ventilation in 38 (49.4%) and 10 patients died (12.9% global, 23.8% at ICU admitted). After multivariate adjustment, TCZ response by BCRSS (OR 0.03 (0.01-0.68), p = 0.028), and Charlson index (OR 3.54 (1.20-10.44), p = 0.022) has been identified as independent factors associated with mortality. Median of hospital stay was 16.0 days (11.0-23.0); BCRSS, physician subjective and D-dimer response were associated with shorter hospitalization stay.Conclusions: In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent8es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCOVID19 pneumoniaes_ES
dc.subjectTocilizumabes_ES
dc.subjectMortalityes_ES
dc.subjectMechanical invasive ventilationes_ES
dc.subjectCase serieses_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes_ES
dc.titleExperience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jaut.2020.102523es_ES
Appears in Collections:
Artículos Medicina Clínica


Thumbnail

View/Open:
 Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of.pdf

1,09 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???